Prokaryotics
Dr. Tomayko is Vice President of Clinical Development at F2G, and is an expert in the Clinical Development of antibiotics with extensive experience in industry in key roles at Pfizer, Spero and GSK.
This person is not in the org chart
This person is not in any offices
Prokaryotics
Prokaryotics is a start-up biotechnology company resulting from licensing several novel antibiotic programs from Merck & Co., Inc. – by a team of former senior scientists at the company including the head of the Antimicrobial Early Discovery Unit, to optimize a number of Merck’s early-stage programs. Prokaryotics has negotiated worldwide rights to develop, manufacture and commercialize pre-clinical assets and programs targeting both Gram-negative and Gram-positive bacteria.